GANX Stock Analysis: Buy, Sell, or Hold?
GANX - Gain Therapeutics, Inc. Common Stock
$1.75
-0.10 (-5.68%)
▼
5d:
-14.46%
30d:
-3.06%
90d:
-10.97%
WAIT
LOW Confidence
Analysis Updated: Apr 29, 2026 12:00 AM ET
Earnings: May 13, 2026
13d
Smart Money Accumulation
GANX is down 11.5% this week, but smart money is accumulating calls. Top strike: $2 2026-06-18 with 2 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When GANX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GANX is down 14.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GANX is down 14.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GANX is currently trading at $1.75, which is considered fair relative to its 30-day fair value range of $1.79 to $2.17.
Technical Outlook: Technically, GANX is in a strong downtrend. The price is currently testing key support at $1.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: GANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.60 (+310.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GANX is in a strong downtrend. The price is currently testing key support at $1.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.7% recently.
Market Sentiment: GANX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $7.60 (+310.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.79 -
$2.17
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
44.7%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.7%)
- BULLISH: Trading 310.8% below Wall St target ($7.60)
Trading Range Analysis
30-Day Trading Range
$1.79 -
$2.17
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.79
Resistance Level
$2.20
Current Trend
Strong Downtrend
Technical data as of
Apr 29, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.97
Wall Street Target
$7.60
(+310.8%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: April 29, 2026 3:17 PM ET
Data refreshes hourly during market hours. Next update: 4:17 PM
Data refreshes hourly during market hours. Next update: 4:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GANX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$107 | 64 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$131 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$27 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 50 HOLD |
